NCT06935175View on ClinicalTrials.gov

A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2028

Conditions
Hepatocellular Cancer
Interventions
DRUG

SHR-1826

SHR-1826 will be administrated per dose level in which the patients are assigned.

DRUG

SHR-1826 and immunotherapy combination therapy

SHR-1826 and immunotherapy will be administrated per dose level in which the patients are assigned.

Trial Locations (1)

200020

Shanghai Zhongshan Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER